mladbrook

Dermal Cell News

VDAC1 Negatively Regulates Melanogenesis through the Ca2+-Calcineurin-CRTC1-MITF Pathway

[Life Science Alliance] Knockdown of VDAC1 increased free cytosolic Ca2+ in cultured melanocytes at the resting state, which activated calcineurin through the Ca2+-calmodulin-CaN pathway.

ROS-Triggered Nanoinducer Based on Dermatan Sulfate Enhances Immunogenic Cell Death in Melanoma

[Journal of Controlled Release] Scientists proposed a nanoinducer based on a functional dermatan sulfate (DS) for melanoma. This nanosystem is composed of DS as framework, aromatic thioketal derivative as functional grafting unit and doxorubicin designed as an immunogenic cell death inducer.

Embigin is a Fibronectin Receptor that Affects Sebaceous Gland Differentiation and Metabolism

[Developmental Cell] Using skin as a model system and combining single-cell RNA-seq data analysis, immunofluorescence, and transgenic mouse models, investigators showed that the transmembrane protein embigin is specifically expressed in the sebaceous gland and that the number of embigin-expressing cells is negatively regulated by Wnt.

Modeling GATA2 Deficiency in Mice: The R396Q Mutation Disrupts Normal Hematopoiesis

[Leukemia] While mutant mice exhibited mild defects in peripheral blood, they displayed significant hematopoietic abnormalities in the bone marrow, including a reduction in hematopoietic stem cell function and intrinsic biases toward specific stem cell subsets that differed from previous models of GATA2 loss.

High Frequency CCR5 Editing in Human Hematopoietic Stem Progenitor Cells Protects Xenograft Mice from HIV Infection

[Nature Communications] Scientists showed the application of CRISPR/Cas9 to achieve >90% CCR5 editing in human, mobilized hematopoietic stem progenitor cells, resulting in a transplant that underwent normal hematopoiesis, produced CCR5 null T cells, and rendered xenograft mice refractory to HIV infection.

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the Phase II TROPION-Lung05 Study

[Journal of Clinical Oncology] The TROPION-Lung05 Phase II trial evaluated the safety and clinical activity of datopotamab deruxtecan in patients with advanced NSCLC with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy.

All Articles by Author:

mladbrook

Popular